Fig. 3From: Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trialInvestigator- and patient-reported assessments at Week 8. Investigator-reported improvement (rating: 1 [very much improved] to 7 [very much worse]) and patient-reported satisfaction (rating: 1 [very satisfied] to 5 [very dissatisfied]) (a) and percentage of composite responders (b). Error bars represent standard deviations. * P ≤ 0.03 vs placebo. CCH, collagenase clostridium histolyticumBack to article page